Primary AldosteronismWAVENCT05405101
Randomised Trial Comparing Thermal Ablation With Adrenalectomy in the Treatment of Unilateral Asymmetric PA
A study testing Thermal ablation of aldosterone producing adenoma. and Unilateral adrenalectomy in people with Primary Aldosteronism, run by Queen Mary University of London at 6 sites in United Kingdom.
Trial summary
The primary objective of WAVE is to test the hypothesis that thermal ablation (microwave or RFA) is non-inferior to surgery in the biochemical (and if so, in the clinical) cure of unilateral PA, according to the international consensus PASO criteria. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Primary Aldosteronism
- What is being tested?
- Thermal ablation of aldosterone producing adenoma. and Unilateral adrenalectomy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 112 participants
- Where
- 6 sitesUnited Kingdom
- Study dates
- 1 Sep 2022to 1 Nov 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age > 18 years
- Primary aldosteronism diagnosed according to international guidelines
- Unilateral disease by AVS or PET-CT criteria
- Ipsilateral radiological abnormality with benign imaging characteristics and technically amenable to both thermal ablation and surgery
- Able and willing to give informed consent
- Randomisation approved by MDT
Who cannot join
- Absolute contraindication to α- or β-adrenoceptor antagonist therapy or CT contrast
- Contraindication or unwillingness for either surgery or thermal ablation
- Inability to withdraw β-adrenoceptor antagonist therapy for 2 weeks
- Unwilling to undergo either LA or thermal ablation
- Unwilling to comply with study visit schedule
- Pregnancy or unwillingness to undertake secure contraception for the study duration (female participants only)
- Life-limiting comorbidity (at the discretion of the PI)
- Clinical and/or biochemical evidence of autonomous cortisol secretion sufficient, in the opinion of the patient's physician, to mandate a unilateral adrenalectomy independent of autonomous aldosterone secretion
Trial locations and contacts
6 sites in 1 country.
6 sites in 1 country
United Kingdom6 sites
Cambridge University Hospitals NHS Foundation Trust
Cambridge, SMLG, CB2 0QQ
St Bartholomew's Hospital
London, EC1A 7BE
University College London Hospital NHS Foundation Trust
London, NW1 2PG
Guy's and St Thomas' NHS Foundation Trust
London, SE1 9RT
Imperial College Healthcare NHS Trust
London, W12 0HS
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, S10 2JF
About this study
Official title: A Prospective Randomised Trial Comparing Thermal Ablation With Laparoscopic Adrenalectomy as an alternatiVE Treatment for Unilateral Asymmetric Primary Aldosteronism
The primary objective of WAVE is to test the hypothesis that thermal ablation (microwave or RFA) is non-inferior to surgery in the biochemical (and if so, in the clinical) cure of unilateral PA, according to the international consensus PASO criteria.
Secondary objectives are to determine whether either intervention is superior to the other in relation to the following outcomes. Where no superiority of either intervention is established, non-inferiority of thermal ablation against adrenalectomy will be sought.
Read more
- Frequency and severity of adverse events
- Length of inpatient stay
- Patient satisfaction
- Quality of life
- Return to activities of daily living
An additional secondary objective in the thermal ablation group alone will be anatomical efficacy of ablation.
Read the detailed description
Primary aldosteronism (PA) results from renin-independent aldosterone hypersecretion and causes hypertension, often with associated hypokalaemia and metabolic alkalosis. These are due to enhanced mineralocorticoid receptor-mediated renal sodium retention and potassium excretion. PA is the commonest cause of secondary hypertension and is responsible for 5-10% of all hypertension, rising to in excess of 20% of resistant cases. Very low diagnosis rates result from a generation of doctors schooled on order-of-magnitude lower estimates, but recent findings suggest that even the 5-10% prevalence may be a considerable under-estimate. In addition to its frequency, PA is a high-risk subset of hypertension and is associated with a two-fold increased risk of cardiovascular events and atrial fibrillation compared to comparable patients with essential hypertension, as well as a reduced quality of life.
Aldosterone excess in PA can originate from one or both adrenal glands. Patients with PA are considered to divide ~50:50 into those with a curable unilateral aldosterone-producing adenoma (APA), and those with bilateral idiopathic adrenal hyperplasia (IAH). For patients with unilateral PA, surgical removal of the affected gland (adrenalectomy) is highly likely to cure the biochemical abnormality, reverse the excess cardiovascular and stroke risks, and is strongly supported by international guidelines.
Whilst directed medical therapies against aldosterone excess exist (e.g. mineralocorticoid receptor antagonists, MRAs), they are inferior to surgery in reducing the excess cardiovascular and stroke risk and improving quality of life. Furthermore, sufficient MRA dosing to de-suppress renin and reverse this excess risk is only achieved in one-third of medically-treated patients. The case for definitive intervention in unilateral PA is therefore compelling, and recommended whenever possible. At present, this is achieved by laparoscopic adrenalectomy (LA), which involves a general anaesthetic, inpatient admission and removal of the entire adrenal gland to treat a condition caused by a small (usually <2cm diameter, often <1cm) benign APA.
An alternative intervention to LA, and the focus of this trial, is selective thermal ablation (by radiofrequency or microwave) of the identified APA(s). Thermal ablation is a technique in which targeted and directed tissue death can be achieved with precision under image guidance, sparing the normal adrenal gland. It is widely established in the treatment of benign and malignant hepatic and renal neoplasms as an alternative to conventional surgery. For these indications, thermal ablation techniques have transformed practice, not only providing high-risk surgical patients with a previously unobtainable curative treatment option but also becoming an accepted mainstay of treatment for small lesions (of the size encountered in PA) in all patients regardless of surgical risk.
We propose a multi-centre prospective randomised trial comparing adrenalectomy (LA) and thermal ablation for the treatment of unilateral APAs. This study is powered to demonstrate non-inferiority of biochemical and clinical response to thermal ablation, compared to the current standard of care, adrenalectomy. The rationale for a non-inferiority trial is that subsequent preference for thermal ablation over surgery will be driven by thermal ablation's greater patient-acceptability and availability, rather than an implausible superior efficacy of sub-total than total adrenalectomy in curing PA. Once safety and efficacy are proven as comparable to those of adrenalectomy, thermal ablation has potential for superiority over medical treatment in several patient groups ineligible for WAVE, e.g., some with bilateral disease, or in whom lateralisation could not be performed.
- Conditions
- Primary Aldosteronism
- Being tested
- Thermal ablation of aldosterone producing adenoma., Unilateral adrenalectomy
- Keywords
- Thermal, Ablation, Laparoscopic, Adrenalectomy
- Medical subject headings
- Hyperaldosteronism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Thermal ablation of aldosterone producing adenoma.Procedure or surgery
On the left side, Radiofrequency ablation of aldosterone producing adenoma(s) will be undertaken via the stomach (endoscopically), under transgastric ultrasound guidance.
On the right side, either Radiofrequency or Microwave Ablation of aldosterone producing adenoma(s) will be performed via a percutaneous approach, under CT guidance.
Unilateral adrenalectomyProcedure or surgery
Also called Laparoscopic adrenalectomy
Unilateral total adrenalectomy for aldosterone producing adenoma. This will be laparoscopic in the vast majority of patients, with open conversion if surgically indicated (unlikely in >1-2 patients)
| Study group | Role | What they receive |
|---|---|---|
| Thermal ablation of adrenal aldosterone producing adenoma (s) | Experimental | For patients randomized to ablation, thermal ablation (either microwave or radiofrequency ablation) will be deployed to treat the adrenal aldosterone producing adenoma(s) Receives: Procedure: Thermal ablation of aldosterone producing adenoma. |
| Unilateral adrenalectomy for aldosterone producing adenoma (s) | Other | For patients randomized to surgery, unilateral adrenalectomy will be performed to remove aldosterone producing adenoma(s) Receives: Procedure: Unilateral adrenalectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Complete biochemical cure of PA
Complete biochemical cure of PA, defined (whilst off medications that might alter serum potassium, renin or aldosterone) by both:
- Normalisation of serum potassium, and
- Normalisation of ARR, or
- Elevated ARR and
- Baseline PAC <190 pmol/L, on immunoassay (<160 pmol/L on mass spectrometry) or ii. Normal confirmatory test (as defined in the inclusion criteria)
Measured: 6 months post intervention
Complete clinical cure of PA
Complete clinical cure of PA, defined as normotension without antihypertensive medication
These criteria have been defined in the international consensus PASO statement, which has become the established yardstick by which PA cure is judged. In this, normotension is defined, in accordance with the European Society of Hypertension guidelines, as <140/80 in the office, <135/85 at home or daytime ambulatory monitoring and <130/80 for 24h ambulatory blood pressure monitoring (24hABPM).
Measured: 6 months post intervention
Secondary outcomes (13)
Adverse events
- Will be directly sought at each study visit through history and physical examination where appropriate
- Participants will be encouraged to report between study visits and will have a mechanism to do so
- Will be classified by system, seriousness, causal relationship and expectedness according to the Common Terminology Criteria for Adverse Events v5.0 (CTCAE)
Measured: Reported throughout the study period.
Anaemia (FBC, requirement for blood transfusion)
Blood test
Measured: 6, 12, 24 and 36 months post intervention
Renal dysfunction and electrolyte abnormalities (U&Es)
Blood test
Measured: 6, 12, 24 and 36 months post intervention
Liver dysfunction (LFTs)
Blood test
Measured: 6, 12, 24 and 36 months post intervention
Pancreatitis (lipase/amylase)
Blood test
Measured: 6, 12, 24 and 36 months post intervention
Hypertensive urgency (physiological parameters, plasma metanephrines)
Blood test
Measured: 6, 12, 24 and 36 months post intervention
Length of inpatient stay (hospital episode data)
Hospital episode data
Measured: 6 weeks post intervention
Patient satisfaction (Freiburg index of patient satisfaction)
Completed by patient, using the FIPs score values to rate the treatment they have received.
Measured: 6 weeks post intervention
Quality of life questionnaire
Completed by patient, using the EQ-5D-5L and SF-36 questionnaire models to score self-rated health and quality of life values. These 2 models are presented as one questionnaire to the patient.
Measured: 6 months post intervention
Return to usual activities of daily living (self-reported)
As reported by patient
Measured: 6 weeks post intervention
Anatomical efficacy of ablation
Ablation group only; post-ablation Metomidate/CETO PET-CT appearances
Measured: 3-6 months post intervention
Partial biochemical cure
Partial biochemical cure of PA, as determined by the international consensus PASO statement
Measured: 6 months post intervention
Partial clinical cure
Partial clinical cure of PA, as determined by the international consensus PASO statement.
Measured: 6 months post intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jun 2022
- Study start1 Sep 2022
- Primary completion1 Nov 2026 (estimated)
- Study completion1 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Primary AldosteronismStudies of the same condition, open and under way.
- More trials run by Queen Mary University of LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Model description
- PROBE: Prospective Randomised open blinded end point study. Patients are randomized using a minimization program. 2:3 Surgery: Ablation
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 112 participants (actual)
Sponsor and investigators
- Lead sponsor
- Queen Mary University of London
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Morris Brown, Principal investigator, Queen Mary University of London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05405101
- Sponsor's protocol ID
- 304174
- Acronym
- WAVE
- Status last verified
- Oct 2026
- First submitted
- 15 Mar 2022
- Last updated
- 2 Nov 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Clinical trial data may be made available to qualified academic researchers upon approval by the study management committee and completion of appropriate data-sharing and transfer agreements. Data requests must include a clear rationale, the relevance of the proposed research, and a description of the hypothesis, research methodology, statistical analysis plan and intended publication plan.
Publications
Laycock K, Kearney J, Lee YN, Macfarlane J, Goodchild E, Ng E, Pineau Mitchell A, Wu X, Htut Z, Goodchild G, Lowe D, Hilliard N, Godfrey E, Qazi N, Bastos J, Chua A, Mahroof R, Palma A, Khatun A, Varsani C, Benu D, Pereira SP, Krishnamurthy M, Cheow H, Chung TT, Carroll P, O'Toole S, Wernig F, Gurnell M, Brown M, Drake WM. Prospective randomised trial comparing thermal ablation With laparoscopic Adrenalectomy as an alternatiVE treatment for unilateral asymmetric primary aldosteronism: a protocol for the WAVE trial. BMJ Open. 2026 Mar 26;16(3):e111798. doi: 10.1136/bmjopen-2025-111798.
PubMed 41887640
Study at a glance
From the registry record, last updated by the sponsor on 2 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Randomised Trial Comparing Thermal Ablation With Laparoscopic Adrenalectomy as an alternatiVE Treatment for Unilateral Asymmetric Primary Aldosteronism
- ClinicalTrials.gov ID
- NCT05405101
- Acronym / sponsor ID
- WAVE / 304174
- Conditions
- Primary Aldosteronism
- Keywords
- Thermal, Ablation, Laparoscopic, Adrenalectomy
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 112 participants (actual)
- Lead sponsor
- Queen Mary University of LondonUniversity, hospital or other
- Study start
- 1 Sep 2022 (actual)
- Primary completion
- 1 Nov 2026 (estimated)
- Study completion
- 1 Nov 2026 (estimated)
- First posted
- 6 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of WAVE is to test the hypothesis that thermal ablation (microwave or RFA) is non-inferior to surgery in the biochemical (and if so, in the clinical) cure of unilateral PA, according to the international consensus PASO criteria.
Secondary objectives are to determine whether either intervention is superior to the other in relation to the following outcomes. Where no superiority of either intervention is established, non-inferiority of thermal ablation against adrenalectomy will be sought.
- Frequency and severity of adverse events
- Length of inpatient stay
- Patient satisfaction
- Quality of life
- Return to activities of daily living
An additional secondary objective in the thermal ablation group alone will be anatomical efficacy of ablation.
Detailed description
Primary aldosteronism (PA) results from renin-independent aldosterone hypersecretion and causes hypertension, often with associated hypokalaemia and metabolic alkalosis. These are due to enhanced mineralocorticoid receptor-mediated renal sodium retention and potassium excretion. PA is the commonest cause of secondary hypertension and is responsible for 5-10% of all hypertension, rising to in excess of 20% of resistant cases. Very low diagnosis rates result from a generation of doctors schooled on order-of-magnitude lower estimates, but recent findings suggest that even the 5-10% prevalence may be a considerable under-estimate. In addition to its frequency, PA is a high-risk subset of hypertension and is associated with a two-fold increased risk of cardiovascular events and atrial fibrillation compared to comparable patients with essential hypertension, as well as a reduced quality of life.
Aldosterone excess in PA can originate from one or both adrenal glands. Patients with PA are considered to divide ~50:50 into those with a curable unilateral aldosterone-producing adenoma (APA), and those with bilateral idiopathic adrenal hyperplasia (IAH). For patients with unilateral PA, surgical removal of the affected gland (adrenalectomy) is highly likely to cure the biochemical abnormality, reverse the excess cardiovascular and stroke risks, and is strongly supported by international guidelines.
Whilst directed medical therapies against aldosterone excess exist (e.g. mineralocorticoid receptor antagonists, MRAs), they are inferior to surgery in reducing the excess cardiovascular and stroke risk and improving quality of life. Furthermore, sufficient MRA dosing to de-suppress renin and reverse this excess risk is only achieved in one-third of medically-treated patients. The case for definitive intervention in unilateral PA is therefore compelling, and recommended whenever possible. At present, this is achieved by laparoscopic adrenalectomy (LA), which involves a general anaesthetic, inpatient admission and removal of the entire adrenal gland to treat a condition caused by a small (usually <2cm diameter, often <1cm) benign APA.
An alternative intervention to LA, and the focus of this trial, is selective thermal ablation (by radiofrequency or microwave) of the identified APA(s). Thermal ablation is a technique in which targeted and directed tissue death can be achieved with precision under image guidance, sparing the normal adrenal gland. It is widely established in the treatment of benign and malignant hepatic and renal neoplasms as an alternative to conventional surgery. For these indications, thermal ablation techniques have transformed practice, not only providing high-risk surgical patients with a previously unobtainable curative treatment option but also becoming an accepted mainstay of treatment for small lesions (of the size encountered in PA) in all patients regardless of surgical risk.
We propose a multi-centre prospective randomised trial comparing adrenalectomy (LA) and thermal ablation for the treatment of unilateral APAs. This study is powered to demonstrate non-inferiority of biochemical and clinical response to thermal ablation, compared to the current standard of care, adrenalectomy. The rationale for a non-inferiority trial is that subsequent preference for thermal ablation over surgery will be driven by thermal ablation's greater patient-acceptability and availability, rather than an implausible superior efficacy of sub-total than total adrenalectomy in curing PA. Once safety and efficacy are proven as comparable to those of adrenalectomy, thermal ablation has potential for superiority over medical treatment in several patient groups ineligible for WAVE, e.g., some with bilateral disease, or in whom lateralisation could not be performed.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- PROBE: Prospective Randomised open blinded end point study. Patients are randomized using a minimization program. 2:3 Surgery: Ablation
| Arm | Type | Receives |
|---|---|---|
| Thermal ablation of adrenal aldosterone producing adenoma (s) | Experimental | Procedure: Thermal ablation of aldosterone producing adenoma.For patients randomized to ablation, thermal ablation (either microwave or radiofrequency ablation) will be deployed to treat the adrenal aldosterone producing adenoma(s) |
| Unilateral adrenalectomy for aldosterone producing adenoma (s) | Other | Procedure: Unilateral adrenalectomyFor patients randomized to surgery, unilateral adrenalectomy will be performed to remove aldosterone producing adenoma(s) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age > 18 years
- Primary aldosteronism diagnosed according to international guidelines
- Unilateral disease by AVS or PET-CT criteria
- Ipsilateral radiological abnormality with benign imaging characteristics and technically amenable to both thermal ablation and surgery
- Able and willing to give informed consent
Key exclusion criteria (8 listed)
- Absolute contraindication to α- or β-adrenoceptor antagonist therapy or CT contrast
- Contraindication or unwillingness for either surgery or thermal ablation
- Inability to withdraw β-adrenoceptor antagonist therapy for 2 weeks
- Unwilling to undergo either LA or thermal ablation
- Unwilling to comply with study visit schedule
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Thermal ablation of aldosterone producing adenoma.On the left side, Radiofrequency ablation of aldosterone producing adenoma(s) will be undertaken via the stomach (endoscopically), under transgastric ultrasound guidance. On the right side, either Radiofrequency or Microwave Ablation of aldosterone producing adenoma(s) will be performed via a percutaneous approach, under CT guidance. | Procedure or surgery | Thermal ablation of adrenal aldosterone producing adenoma (s) |
| Unilateral adrenalectomyAlso: Laparoscopic adrenalectomyUnilateral total adrenalectomy for aldosterone producing adenoma. This will be laparoscopic in the vast majority of patients, with open conversion if surgically indicated (unlikely in >1-2 patients) | Procedure or surgery | Unilateral adrenalectomy for aldosterone producing adenoma (s) |
Primary outcome
Complete biochemical cure of PA
Time frame: 6 months post intervention
Complete biochemical cure of PA, defined (whilst off medications that might alter serum potassium, renin or aldosterone) by both: 1. Normalisation of serum potassium, and 2. Normalisation of ARR, or 3. Elevated ARR and i. Baseline PAC <190 pmol/L, on immunoassay (<160 pmol/L on mass spectrometry) or ii. Normal confirmatory test (as defined in the inclusion criteria)
Complete clinical cure of PA
Time frame: 6 months post intervention
Complete clinical cure of PA, defined as normotension without antihypertensive medication These criteria have been defined in the international consensus PASO statement, which has become the established yardstick by which PA cure is judged. In this, normotension is defined, in accordance with the European Society of Hypertension guidelines, as <140/80 in the office, <135/85 at home or daytime ambulatory monitoring and <130/80 for 24h ambulatory blood pressure monitoring (24hABPM).
13 secondary outcomes
Adverse events
Time frame: Reported throughout the study period.
Anaemia (FBC, requirement for blood transfusion)
Time frame: 6, 12, 24 and 36 months post intervention
Renal dysfunction and electrolyte abnormalities (U&Es)
Time frame: 6, 12, 24 and 36 months post intervention
Liver dysfunction (LFTs)
Time frame: 6, 12, 24 and 36 months post intervention
Pancreatitis (lipase/amylase)
Time frame: 6, 12, 24 and 36 months post intervention
Hypertensive urgency (physiological parameters, plasma metanephrines)
Time frame: 6, 12, 24 and 36 months post intervention
Length of inpatient stay (hospital episode data)
Time frame: 6 weeks post intervention
Patient satisfaction (Freiburg index of patient satisfaction)
Time frame: 6 weeks post intervention
Quality of life questionnaire
Time frame: 6 months post intervention
Return to usual activities of daily living (self-reported)
Time frame: 6 weeks post intervention
Anatomical efficacy of ablation
Time frame: 3-6 months post intervention
Partial biochemical cure
Time frame: 6 months post intervention
Partial clinical cure
Time frame: 6 months post intervention
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Nov 2026.
- Derived from this study: PubMed 41887640Laycock K, Kearney J, Lee YN, Macfarlane J, Goodchild E, Ng E, Pineau Mitchell A, Wu X, Htut Z, Goodchild G, Lowe D, Hilliard N, Godfrey E, Qazi N, Bastos J, Chua A, Mahroof R, Palma A, Khatun A, Varsani C, Benu D, Pereira SP, Krishnamurthy M, Cheow H, Chung TT, Carroll P, O'Toole S, Wernig F, Gurnell M, Brown M, Drake WM. Prospective randomised trial comparing thermal ablation With laparoscopic Adrenalectomy as an alternatiVE treatment for unilateral asymmetric primary aldosteronism: a protocol for the WAVE trial. BMJ Open. 2026 Mar 26;16(3):e111798. doi: 10.1136/bmjopen-2025-111798.
- Individual participant dataSharing planned: Yes. Clinical trial data may be made available to qualified academic researchers upon approval by the study management committee and completion of appropriate data-sharing and transfer agreements. Data requests must include a clear rationale, the relevance of the proposed research, and a description of the hypothesis, research methodology, statistical analysis plan and intended publication plan.
Related trials for Primary Aldosteronism
Not yet recruitingPhase 2
SYH2072 Tablets in Participants With Primary Aldosteronism
Primary Aldosteronism
Recruiting
Trial of Aldosterone-hybrid SteRoid for Guiding curablE Treatment of Primary Aldosteronism (TARGET-PA)
Hyperaldosteronism; Primary, Primary Aldosteronism Due to Aldosterone Producing Adenoma
RecruitingObservational study
Kidney Stiffness Measured by Ultrasound in Patients With High Blood Pressure and Healthy Volunteers
Arterial Hypertension, Chronic Kidney Disease, Primary Aldosteronism
Active, not recruiting
Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension
Primary Aldosteronism, Resistant Hypertension
RecruitingObservational study
Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks
Adrenal Gland Neoplasm, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Morris Brown principal investigator
Queen Mary University of London
6 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Thermal ablation of aldosterone producing adenoma. and Unilateral adrenalectomy in people with Primary Aldosteronism, run by Queen Mary University of London at 6 sites in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 2 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Complete biochemical cure of PA (time frame: 6 months post intervention). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05405101, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2026.